Disease modifying anti-rheumatic drug treatment cycles and rates of flare in juvenile idiopathic arthritis—a tale of Sisyphean endeavour?
Authors' conclusion
In JIA patients requiring DMARD therapy, recurrent treatment withdrawal trials are common over follow-up, but relapse risk is high and remains so over successive trials.
Study context
- Population
- Children with DMARD-treated JIA diagnosed between 2010 and 2014; data collected to January 2024
- Participants
- 91 children
- Outcome
- Frequency of medication withdrawal trials over follow-up and relapse rates over consecutive DMARD treatment cycles
Methodological detailslongitudinal cohort data, Median age 10.1 years (range 1.5-16.8); 59% female; median follow-up 7.0 years (range 0.7-13)
- Longitudinal cohort data
- Median age 10.1 years (range 1.5-16.8); 59% female; median follow-up 7.0 years (range 0.7-13)
Main finding
As reported in the abstract
DMARD treatment cycles, relapse and remaining off treatment
- Children with more than one DMARD cycle
- 44%
- Relapse after first cycle
- 63.5%
- Relapse after second cycle
- 53.3%
- Off treatment to last follow-up after cycle 1
- 25.3%
- Off treatment to last follow-up over two subsequent cycles
- 35.2%
- Maximum number of DMARD cycles
- 4
Observational data: associations, not effects.
Original publication
Disease modifying anti-rheumatic drug treatment cycles and rates of flare in juvenile idiopathic arthritis—a tale of Sisyphean endeavour? Rheumatology (Oxford). Published 9 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →